In Depth Research on Global Radiopharmaceuticals Market Outlook 2020

“Global Radiopharmaceuticals Market Outlook 2020” Report Highlight:

* Global Radiopharmaceutical Market Overview
* Global Radiopharmaceuticals Market Dynamics
* FDA & EMA Guidelines for Radiopharmaceuticals
* Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
* Global Radiopharmaceuticals Clinical Pipeline: 133 Radiopharmaceuticals
* Majority Radiopharmaceuticals in Preclinical Phase: 44 Radiopharmaceuticals
* Marketed Radiopharmaceuticals: 19 Radiopharmaceuticals

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Radiopharmaceuticals-Market-Outlook-2020.php

Table of Contents

1. Global Radiopharmaceutical Market Overview
1.1 Current Market Scenario
1.2 Diagnostic & Therapeutic Radiopharmaceuticals
1.3 Global Radiopharmaceticals Clinical Pipeline Overview

2. Global Radiopharmaceuticals Market Dynamics

3. Radioisotopes Used in Radiopharmaceuticals

4. EMA Guidelines for Radiopharmaceuticals
4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products
4.2 Toxicological & Pharmacological Tests
4.3 Clinical Documentation
4.4 Radiation Dosimetry
4.5 Labelling & Packaging

5. FDA Guidelines for Radiopharmaceuticals
5.1 Clinical Indication
5.2 General Considerations for Safety Assessments
5.3 Clinical Evaluation of Medical Imaging Agents

6. Canada Guidelines for Radiopharmaceuticals
6.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research
6.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans
6.3 Stability Testing of Existing Drug Substances and Products
6.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)

7. Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Phase-0
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration

8. Marketed Radiopharmaceuticals Clinical Insight by Indication
8.1 Florbetapir F 18 (Amyvid)
8.2 Iobenguane I-123 (AdreView)
8.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
8.4 Radium-223 Chloride (Alpharadin & Xofigo)
8.5 Tc 99m Tilmanocept (Lymphoseek)
8.6 Florbetaben F18 (NeuraCeq)
8.7 Capromab (ProstaScint)
8.8 Pentetreotide (Oktreotid & 111In)
8.9 Iodine I 131 Derlotuximab Biotin (Cotara)
8.10 Tc 99m Besilesomab (Scintimun)
8.11 Samarium 153 lexidronam (Quadramet)
8.12 Technetium Tc 99m Sulfur Colloid Injection
8.13 Tc 99m Apcitide (AcuTect)
8.14 DW 166HC (Milican)
8.15 Tc 99m Sulesomab (LeukoScan)
8.16 Satumomab (OncoScint CR/OV)
8.17 Pentetreotide (OctreoScan & SomatoTher)
8.18 Tc 99m ior cea1
8.19 Tc 99m Nofetumomab Merpentan (VerLuma)

9. Discontinued & Suspended Radiopharmaceuticals by Indication & Phase
9.1 No Development Reported
9.2 Discontinued
9.3 Market Withdrawal
9.4 Suspended


10. Competitive Landscape
10.1 Avid Radiopharmaceuticals
10.2 Actinium Pharmaceuticals
10.3 AREVA Med
10.4 Bayer HealthCare Pharmaceuticals
10.5 Cardinal Health
10.6 Immunomedics
10.7 Lantheus Medical Imaging
10.8 Merck
10.9 Navidea
10.10 Nordion
10.11 Lantheus Medical Imaging
10.12 GE Healthcare
10.13 Ion Beam Applications
10.14 PETNET Solutions (Siemens Healthcare Global)

Figure 1-1: Global Radiopharmaceuticals Market (US$ Billion), 2014-2020
Figure 1-2: Global Radiopharmaceuticals Market by Region (%), 2014 & 2020
Figure 1-3: Global Radiopharmaceuticals Market by Region (US$ Billion), 2014 - 2020
Figure 1-4: Target Patient Base for Radiopharmaceuticals (Million), 2014-2020
Figure 1-5: Target Patient Base for Radiopharmaceuticals by Region (%), 2014 & 2020
Figure 1-6: Target Patient Base for Radiopharmaceuticals by Region (Million), 2014 - 2020
Figure 1-7: Global Radiopharmceutical Pipeline by Phase (%), 2016
Figure 1-8: Global Radiopharmceutical Pipeline by Phase (Numbers), 2016
Figure 1-9: Suspended & Discontinued Radiopharmceutical Pipeline (%), 2016
Figure 1-10: Suspended & Discontinued Radiopharmceutical Pipeline (Number), 2016
Figure 8-1: Lantheus Medical Imaging Product Pipeline

Table 1-1: Calcium-47 Investigation Properties as Radiopharmaceuticals Drug
Table 1-2: Carbon-11 Investigation Properties as Radiopharmaceuticals Drug
Table 1-3: Carbon-14 Investigation Properties as Radiopharmaceuticals Drug
Table 1-4: Chromium-51 Investigation Properties as Radiopharmaceuticals Drug
Table 1-5: Cobalt-57 Investigation Properties as Radiopharmaceuticals Drug
Table 1-6: Cobalt-58 Investigation Properties as Radiopharmaceuticals Drug
Table 1-7: Erbium-169 Investigation Properties as Radiopharmaceuticals Drug
Table 1-8: Fluorine-18 Investigation Properties as Radiopharmaceuticals Drug
Table 1-9: Gallium-67 Investigation Properties as Radiopharmaceuticals Drug
Table 1-10: Gallium-68 Investigation Properties as Radiopharmaceuticals Drug
Table 1-11: Hydrogen-3 Investigation Properties as Radiopharmaceuticals Drug
Table 1-12: Indium-111 Investigation Properties as Radiopharmaceuticals Drug
Table 1-13: Iodine-123 Investigation Properties as Radiopharmaceuticals Drug
Table 1-14: Iodine-125 Investigation Properties as Radiopharmaceuticals Drug
Table 1-15: Iodine-131 Diagnostic Investigation Properties as Radiopharmaceuticals Drug
Table 1-16: Iodine-131 Therapeutic Investigation Properties as Radiopharmaceuticals Drug
Table 1-17: Iron-59 Investigation Properties as Radiopharmaceuticals Drug
Table 1-18: Krypton-81m Investigation Properties as Radiopharmaceuticals Drug
Table 1-19: Nitrogen-13 Investigation Properties as Radiopharmaceuticals Drug
Table 1-20: Oxygen-15 Investigation Properties as Radiopharmaceuticals Drug
Table 1-21: Phosphorus-32 Investigation Properties as Radiopharmaceuticals Drug
Table 1-22: Radium-223 Investigation Properties as Radiopharmaceuticals Drug
Table 1-23: Rubidium-82 Investigation Properties as Radiopharmaceuticals Drug
Table 1-24: Samarium-153 Investigation Properties as Radiopharmaceuticals Drug
Table 1-25: Selenium-75 Investigation Properties as Radiopharmaceuticals Drug
Table 1-26: Sodium-22 Investigation Properties as Radiopharmaceuticals Drug
Table 1-27: Sodium-24 Investigation Properties as Radiopharmaceuticals Drug
Table 1-28: Strontium-89 Investigation Properties as Radiopharmaceuticals Drug
Table 1-29: Technetium-99m Investigation Properties as Radiopharmaceuticals Drug
Table 1-30: Thallium-201 Investigation Properties as Radiopharmaceuticals Drug
Table 1-31: Xenon-133 Investigation Properties as Radiopharmaceuticals Drug
Table 1-32: Yttrium-90 Investigation Properties as Radiopharmaceuticals Drug

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.